Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease

Cancer Research

Volumn 74, Issue 12, 2014, Pages 3248-3258

  Catsburg, Chelsea ^a   Gunter, Marc J ^g   Chen, Chu ^c   Cote, Michele L ^d   Kabat, Geoffrey C ^a   Nassir, Rami ^e   Tinker, Lesley ^c   Wactawski Wende, Jean ^b   Page, David L ^f   Rohan, Thomas E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; ESTRADIOL; ESTROGEN; INSULIN; PROGESTERONE;

ADULT; AGED; ARTICLE; BENIGN PROLIFERATIVE BREAST DISEASE; BREAST DISEASE; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN BLOOD LEVEL; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADIPONECTIN; AGED; BREAST NEOPLASMS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INSULIN; MIDDLE AGED; POSTMENOPAUSE; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84903449144     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3514     Document Type: Article

References (54)

1. Rohan T, Kandel R. Breast. In:Franco EL, Rohan TE, editors. Cancer precursors: epidemiology, detection, and prevention. New York: Springer-Verlag; 2002. p. 232-48.
2. Silvera SA, Rohan TE. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Res Treat 2008;110:397-409. (Pubitemid 351962587)
3. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4: 579-91. (Pubitemid 39025053)
4. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011;11:886-95.
5. Key TJ. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids 2011;76:812-5.
6. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982;59:680-6. (Pubitemid 12107424)
7. Lazarus R, Sparrow D, Weiss S. Temporal relations between obesity and insulin: longitudinal data from the Normative Aging Study. Am J Epidemiol 1998;147:173-9. (Pubitemid 28060489)
8. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997;11:457-65. (Pubitemid 27259987)
9. Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y, et al. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 2008;20:971-7.
10. Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 2003;10:331-45. (Pubitemid 36758659)
11. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002;4:65-9. (Pubitemid 34248122)
12. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
13. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13:S18-77. (Pubitemid 37324176)
14. Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst 2008;100:563-71.
15. Cui Y, Page DL, Chlebowski RT, Beresford SA, Hendrix SL, Lane DS, et al. Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast. Int J Cancer 2007;121:1346-51. (Pubitemid 47293804)
16. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51. (Pubitemid 15192861)
17. Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, Gelman R, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 1992;16:1133-43. (Pubitemid 23004420)
18. Sidawy MK, Stoler MH, Frable WJ, Frost AR, Masood S, Miller TR, et al. Interobserver variability in the classification of proliferative breast lesions by fine-needle aspiration: results of the Papanicolaou Society of Cytopathology Study. Diagn Cytopathol 1998;18:150-65. (Pubitemid 28087018)
19. Bodian CA, Perzin KH, Lattes R, Hoffmann P. Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. Cancer 1993;71:3908-13. (Pubitemid 23172968)
20. Langholz B, Goldstein L. Risk set sampling in epidemiologic cohort studies. Stat Sci 1996;11:35-53. (Pubitemid 126706118)
21. Diaz-Cruz MS, Lopez de Alda MJ, Lopez R, Barcelo D. Determination of estrogens and progestogens by mass spectrometric techniques (GC/MS, LC/MS and LC/MS/MS). J Mass Spectrom 2003; 38:917-23. (Pubitemid 37121807)
22. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101: 48-60.
23. Westley RL, May FE. A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol 2013;2013:632461.
24. Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Draznin B. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem 2001;276:38023-8.
25. Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, Naor D, et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997;40 Suppl 2:S25-31. (Pubitemid 27306919)
26. Heuson JC, Legros N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 1972;32:226-32.
27. Shafie SM, Grantham FH. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 1981;67:51-6. (Pubitemid 11087550)
28. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev 1987;8:132-41.
29. Pugeat M, Crave JC, Elmidani M, Nicolas MH, Garoscio-Cholet M, Lejeune H, et al. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol 1991;40: 841-9.
30. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 2009;125:2704-10.
31. Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR. Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 2002;156: 349-52. (Pubitemid 34858003)
32. Kaaks R, Lundin E, Rinaldi S, Manjer J, Biessy C, Soderberg S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002;13:307-16. (Pubitemid 34553511)
33. Schairer C, Hill D, Sturgeon SR, Fears T, Pollak M, Mies C, et al. Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 2004;108:773-9. (Pubitemid 38076411)
34. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
35. Rohan TE, Miller AB. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 1999;8:123-30. (Pubitemid 29210217)
36. Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, et al. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev 2008; 17:2337-43.
37. Samoli E, Trichopoulos D, Lagiou A, Zourna P, Georgila C, Minaki P, et al. The hormonal profile of benign breast disease. Br J Cancer 2013;108:199-204.
38. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001;38:189-97. (Pubitemid 32786776)
39. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-9; quiz 20.
40. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8. (Pubitemid 29177345)
41. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004;323:630-5. (Pubitemid 39221142)
42. Diez JJ, Iglesias P. The role of the novel adipocyte-derived protein adiponectin in human disease: an update. Mini Rev Med Chem 2010;10:856-69.
43. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101:2476-81. (Pubitemid 38269336)
44. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005;280:18341-7. (Pubitemid 41389081)
45. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens) 2012; 11:8-20.
46. Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
47. Liu LY, Wang M, Ma ZB, Yu LX, Zhang Q, Gao DZ, et al. The role of adiponectin in breast cancer: a meta-analysis. PLoS ONE 2013;8: e73183.
48. Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004;13:220-4. (Pubitemid 38222552)
49. Bluher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol 2010;21:38-43.
50. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995;4:649-54.
51. Gaudet MM, Falk RT, Gierach GL, Lacey JV Jr, Graubard BI, Dorgan JF, et al. Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol 2010;34:580-6.
52. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47: 444-50. (Pubitemid 32222458)
53. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977;105:488-95. (Pubitemid 8112070)
54. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999;187:272-8. (Pubitemid 29064150)